Successful Treatment of Atopic Hand and Foot Eczema with Oral Janus Kinase 1 Inhibition

Abstract

Get full access to this article

View all access options for this article.

References

Thyssen

, Schuttelaar

MLA

, Alfonso

, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis, 2022; 86(5):357–378. doi:10.1111/cod.14035.

Rogner

, Biedermann

, Lauffer

. Treatment of atopic dermatitis with baricitinib: first real-life experience. Acta Derm Venereol, 2022; 102:adv00677. doi:10.2340/actadv.v102.1088.

Nakagawa

, Nemoto

, Igarashi

, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol, 2020; 82(4):823–831. doi:10.1016/j.jaad.2019.12.015.

Rosenberg

, Loman

, Schuttelaar

MLA

. Baricitinib treatment of severe chronic hand eczema: two case reports. Contact Dermatitis, 2022; 86(5):419–421. doi:10.1111/cod.14039.

Guttman Krader

. Dual JAK/SYK inhibitor a promising systemic treatment for chronic hand eczema. Dermatol Times, 2020; 41(8). Available at: https://www.dermatologytimes.com/view/dual-jak-syk-inhibitor-a-promising-systemic-treatment-for-chronic-hand-eczema. Accessed August 30, 2022.